sarah rimmington srimmingtonessentialinformationorg biogenerics help save nearly 100 bn 10 yrs reghu balakrishnan financial express india august 07 2008 httpwwwfinancialexpresscomnewsbiogenericstohelpsavenearly100bnover10yrs345537 mumbai aug 6 efforts indian biotech firms keen enter global biogenerics copycat version biotech drugs market boosted number recent studies carried various companies agencies according studies availability biogenerics would save healthcare system billions dollars year projecting studies generic pharmaceutical association gpha largest association generic companies across globe highlighted necessity biogeneric drugs world study insmed usbased biotech company estimated 67 billion 108 billion savings 10 years 236 billion 378 billion savings 20 years generic versions top 12 categories biologics patents either expired soon expire study conducted behalf pharmaceutical care manufacturers association pcma estimated 149 billion savings standard 10year scoring period certain biopharmaceuticals top 200 medicare part b reimbursed categories us express scripts estimated 71 billion savings 10 years products four therapeutic categories interferons erythropoietin growth hormone insulin patients facing serious conditions cancer heart disease safe affordable biogenerics would allow improve lives reducing health care costs said kathleen jaeger president ceo gpha currently usa accounts 55 biopharmaceuticals market 2010 analysts expect biologic sales us reach nearly 60 billion account quarter overall drug sales though european medicines agency emea approved first biosimilar sandozs omnitrope april 2006 us food drug administration fda approved according frost sullivan biosimilar markets europe us potential generate sales 164 billion 2011 despite dominance mncs indian pharma biotech sector local firms biocon bharat biotech dr reddys labs shantha biotechnics wockhardt selling various biotech drugs like streptokinase human insulin g csf erythropoietin hgh human growth hormone interferon alpha 2b 50 recombinant therapeutic products approved globally around 15 recombinant biotech products marketed country kiran mazumdar shaw chairman managing director biocon told fe believe biogenerics command good market share healthcare bills challenged mounting costs need address affordability biogenerics developed pipeline generic biotech drugs like insulin gcsf epo streptokinase glargine etc already enjoying increased market share several international markets especially insulin interesting see biotech companies enjoyed protection generic competition respond sarah rimmington attorney essential action access medicines project washington dc tel 202 3878030 cell 202 4222687 wwwessentialactionorgaccess _______________________________________________ iphealth mailing list iphealthlistsessentialorg httplistsessentialorgmailmanlistinfoiphealth thu 07 aug 2008 151641 0400 iphealth biogenerics help save nearly 100bn 10 yrs